Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Wilson’s Disease in 28 Major Markets
Wilson's disease, also known as progressive lenticular degeneration, is a genetic disorder inherited in an autosomal recessive manner. It is caused by mutations in a gene coding for a copper-transporting protein with a key role in copper metabolism. Reduced activity of the protein leads to copper accumulation in the body which results in various hepatic, osseous, neurological and psychiatric manifestations. Although the genotype–phenotype correlation is still to be elucidated, therapies that are currently available permit patients to live fairly normal lives. However, hepatic and neurological damage sustained prior to the commencement of therapy can be irreversible.
This report provides the current prevalent population for Wilson's disease across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Bulgaria, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, Wilson's disease patients grouped by genetic features, various symptoms and treatments have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of Wilson's disease include:
• Hepatitis and liver cirrhosis
• Affective disorders
• Back pain and stiffness
• Osteoporosis and frequent bone fractures
• Amenorrhoea
• Fertility problems
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global Wilson's disease market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of Wilson's disease and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Identification of Wilson's disease patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of Wilson's disease patients.
Epiomic Epidemiology Series: Wilson’s Disease Forecast in 28 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR WILSON’S DISEASE
• FEATURES OF WILSON’S DISEASE PATIENTS
• SIGNS AND SYMPTOMS OF WILSON’S DISEASE PATIENTS
• HEPATIC SIGNS AND SYMPTOMS
• NEUROLOGICAL SIGNS AND SYMPTOMS
• PSYCHOLOGICAL SIGNS AND SYMPTOMS
• OPHTHALMOLOGIC SIGNS AND SYMPTOMS
• TREATMENT OF WILSON’S DISEASE PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Prevalence of Wilson’s disease, total (000s)
• Table 2. Prevalence of Wilson’s disease, males (000s)
• Table 3. Prevalence of Wilson’s disease, females (000s)
• Table 4. Patients with Wilson's disease by presence of common mutations, total (000s)
• Table 5. Patients with Wilson's disease by presence of symptoms, total (000s)
• Table 6. Wilson's disease patients with hepatic signs and symptoms, total (000s)
• Table 7. Wilson's disease patients with ascites, total (000s)
• Table 8. Wilson's disease patients with oedema, total (000s)
• Table 9. Wilson's disease patients with splenomegaly, total (000s)
• Table 10. Wilson's disease patients with jaundice, total (000s)
• Table 11. Wilson's disease patients with hepatomegaly, total (000s)
• Table 12. Wilson's disease patients with neurological signs and symptoms, total (000s)
• Table 13. Wilson's disease patients with dystonia, total (000s)
• Table 14. Wilson's disease patients with dysarthria, total (000s)
• Table 15. Wilson's disease patients with tremor, total (000s)
• Table 16. Wilson's disease patients with gait disturbance, total (000s)
• Table 17. Wilson's disease patients with psychological signs and symptoms, total (000s)
• Table 18. Wilson's disease patients with ophthalmologic signs and symptoms, total (000s)
• Table 19. Wilson's disease patients with Kayser–Fleischer ring, total (000s)
• Table 20. Wilson's disease patients receiving treatment, total (000s)
• Table 21. Wilson's disease patients treated with penicillamine, total (000s)
• Table 22. Wilson's disease patients treated with trientine, total (000s)
• Table 23. Wilson's disease patients treated with zinc, total (000s)
• Table 24. Abbreviations and acronyms used in the report
• Table 25. USA prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 26. USA prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 27. Canada prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 28. Canada prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 29. France prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 30. France prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 31. Germany prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 32. Germany prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 33. Italy prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 34. Italy prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 35. Spain prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 36. Spain prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 37. UK prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 38. UK prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 39. Poland prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 40. Poland prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 41. Netherlands prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 42. Netherlands prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 43. Belgium prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 44. Belgium prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 45. Norway prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 46. Norway prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 47. Sweden prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 48. Sweden prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 49. Denmark prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 50. Denmark prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 51. Finland prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 52. Finland prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 53. Austria prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 54. Austria prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 55. Switzerland prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 56. Switzerland prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 57. Ireland prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 58. Ireland prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 59. Bulgaria prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 60. Bulgaria prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 61. Russia prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 62. Russia prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 63. Turkey prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 64. Turkey prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 65. Japan prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 66. Japan prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 67. China prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 68. China prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 69. South Korea prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 70. South Korea prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 71. India prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 72. India prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 73. Australia prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 74. Australia prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 75. Brazil prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 76. Brazil prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 77. Mexico prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 78. Mexico prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
• Table 79. Argentina prevalence of Wilson’s disease by 5-yr age cohort, males (000s)
• Table 80. Argentina prevalence of Wilson’s disease by 5-yr age cohort, females (000s)
